Evidence map›Paper›PMID 28413861›Full record

ArticleCell and tissue research2017

Preconditioning with melatonin improves therapeutic outcomes of bone marrow-derived mesenchymal stem cells in targeting liver fibrosis induced by CCl4.

Keywan Mortezaee, Neda Khanlarkhani, Fatemeh Sabbaghziarani, Saeid Nekoonam, Jamal Majidpoor, Amir Hosseini, Parichehr Pasbakhsh, Iraj Ragerdi Kashani, Adib Zendedel

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Cell and tissue research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Melatonin and the Programming of Stem Cells.International journal of molecular sciences · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Keywan MortezaeeDepartment of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Neda KhanlarkhaniDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh SabbaghziaraniDepartment of Anatomy, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Saeid NekoonamDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Jamal MajidpoorDepartment of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Amir HosseiniDepartment of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Parichehr PasbakhshDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Iraj Ragerdi KashaniDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ragerdi@tums.ac.ir.
Adib ZendedelInstitute of Neuroanatomy, School of Medicine, RWTH Aachen University, 52074, Aachen, Germany.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRKurdistan University of Medical Sciences · IRQazvin University of Medical Sciences · IRRWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preconditioning of mesenchymal stem cells (MSCs) with melatonin (MT) has shown promising results in animal models of myocardial infarction, renal ischemia and cerebral ischemia. Here, we use this strategy in the liver fibrosis induced by CCl4. There were five groups: normal, CCl4, CCl4 + vehicle, CCl4 + BMMSCs and CCl4 + MT-bone marrow (BM)-derived MSCs (MT-BMMSCs). CCl4 was injected twice weekly for 8 weeks and treatment either with cells or vehicle was performed at the beginning of week 5 with a single dose. BMMSCs were preconditioned with MT for 24 h before injection. MT-BMMSCs had a high ability of homing into the injured liver (P ≤ 0.05 vs. BMMSCs). The CCl4 + MT-BMMSCs group showed higher percentage of glycogen storage but lower percentage of collagen and lipid accumulation (P ≤ 0.05 vs. CCl4 + BMMSCs). The CCl4 + MT-BMMSCs group showed lower expressions of transforming growth factor-β1 (TGF-β1) and Bax and lower content of sera alanine aminotransferase (ALT) but higher expressions of matrix metalloproteinases (MMPs) and Bcl2 compared with the BMMSCs group (P ≤ 0.05). The results showed the better therapeutic outcomes of MT preconditioning by probably improving cell homing and also better maintenance of the balance between matrix degrading and accumulating factors.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsBone Marrow CellsCarbon TetrachlorideHydroxyprolineLiver CirrhosisMaleMelatoninMesenchymal Stem CellsRats, Sprague-DawleyCarbon TetrachlorideHydroxyprolineMelatoninBone marrow-derived mesenchymal stem cellsLiverMatrix metalloproteinaseMelatoninPreconditioning

Identifiers

PMID28413861
OpenAlexW2607005461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.